Novel serum protein biomarkers indicative of growth hormone doping in healthy human subjects

Proteomics

Volumn 11, Issue 17, 2011, Pages 3565-3571

  Ding, Juan ^a   Okada, Shigeru ^a,b   Jørgensen, Jens Otto Lunde ^c   Kopchick, John J ^a  

^a OHIO UNIVERSITY   (United States)

^b OHIO UNIVERSITY   (United States)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

2 DE; Biomarker; Biomedicine; Doping; Growth hormone

Indexed keywords

ALPHA 1 ANTITRYPSIN; APOLIPOPROTEIN A1; BIOLOGICAL MARKER; HEMOGLOBIN BETA CHAIN; HUMAN GROWTH HORMONE; INTER ALPHA TRYPSIN INHIBITOR; INTER ALPHA TRYPSIN INHIBITOR HEAVY CHAIN H4; PLASMA PROTEIN; PREALBUMIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; DOPING; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS;

ADULT; BLOOD PROTEINS; DOPING IN SPORTS; DOUBLE-BLIND METHOD; HUMAN GROWTH HORMONE; HUMANS; MALE; PROTEOMICS; RECOMBINANT PROTEINS; SUBSTANCE ABUSE DETECTION; YOUNG ADULT;

EID: 80051825974     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.201100077     Document Type: Article

References (32)

1. Rubeck, K. Z., Bertelsen, S., Vestergaard, P., Jorgensen, J. O., Impact of GH substitution on exercise capacity and muscle strength in GH-deficient adults: a meta-analysis of blinded, placebo-controlled trials. Clin. Endocrinol. (Oxf.) 2009, 71, 860-866.
2. Meinhardt, U., Nelson, A. E., Hansen, J. L., Birzniece, V. et al., The effects of growth hormone on body composition and physical performance in recreational athletes. Ann. Intern. Med. 2010, 152, 568-577.
3. Saugy, M., Robinson, N., Saudan, C., Baume, N. et al., Human growth hormone doping in sport. Br. J. Sports Med. 2006, 40, i35-i39.
4. Ho, K. K. Y., Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II: a statement of the GH Research Society in association with the European Society for Pediatric Endocrinology, Lawson Wilkins Society, European Society of Endocrinology, Japan Endocrine Society, and Endocrine Society of Australia. Eur. J. Endocrinol. 2007, 157, 695-700.
5. Holl, R. W., Schwarz, U., Schauwecker, P., Benz, R. et al., Diurnal variation in the elimination rate of human growth hormone (GH): the half-life of serum GH is prolonged in the evening, and affected by the source of the hormone, as well as by body size and serum estradiol. J. Clin. Endocrinol. Metab. 1993, 77, 216-220.
6. Baumann, G. P., Growth hormone isoforms. Growth Horm. IGF Res. 2009, 19, 333-340.
7. Wu, Z., Bidlingmaier, M., Dall, R., Strasburger, C. J., Detection of doping with human growth hormone. Lancet 1999, 353, 895.
8. Travis, J., Growth hormone test finally nabs first doper. Science 2010, 327, 1185.
9. Dall, R., Longobardi, S., Ehrnborg, C., Keay, N. et al., The effect of four weeks of supraphysiological growth hormone administration on the insulin-like growth factor axis in women and men. GH-2000 Study Group. J. Clin. Endocrinol. Metab. 2000, 85, 4193-4200.
10. Longobardi, S., Keay, N., Ehrnborg, C., Cittadini, A. et al., Growth hormone (GH) effects on bone and collagen turnover in healthy adults and its potential as a marker of GH abuse in sports: a double blind, placebo-controlled study. The GH-2000 Study Group. J. Clin. Endocrinol. Metab. 2000, 85, 1505-1512.
11. Nguyen, T. V., Nelson, A. E., Howe, C. J., Seibel, M. J. et al., Within-subject variability and analytic imprecision of insulinlike growth factor axis and collagen markers: implications for clinical diagnosis and doping tests. Clin. Chem. 2008, 54, 1268-1276.
12. Krag, M. B., Gormsen, L. C., Guo, Z., Christiansen, J. S. et al., Growth hormone-induced insulin resistance is associated with increased intramyocellular triglyceride content but unaltered VLDL-triglyceride kinetics. Am. J. Physiol. Endocrinol. Metab. 2007, 292, E920-E927.
13. Bradford, M. M., A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 72, 248-254.
14. List, E. O., Berryman, D. E., Palmer, A. J., Qiu, L. et al., Analysis of mouse skin reveals proteins that are altered in a diet-induced diabetic state: a new method for detection of type 2 diabetes. Proteomics 2007, 7, 1140-1149.
15. Qiu, L., List, E. O., Kopchick, J. J., Differentially expressed proteins in the pancreas of diet-induced diabetic mice. Mol. Cell. Proteomics 2005, 4, 1311-1318.
16. Sackmann-Sala, L., Ding, J., Frohman, L. A., Kopchick, J. J., Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Horm. IGF Res. 2009, 19, 471-477.
17. Okada, S., List, E. O., Sankaran, S., Kopchick, J. J., Plasma protein biomarkers correlated with the development of diet-induced type 2 diabetes in mice. Clin. Proteomics 2010, 6, 6-17.
18. Ding, J., Kopchick, J. J., Plasma biomarkers of mouse aging. Age (Dordr) 2010 (Epub ahead of print).
19. Christensen, B., Sackmann-Sala, L., Cruz-Topete, D., Jorgensen, J. O. et al., Novel serum biomarkers for erythropoietin use in humans: a proteomic approach. J. Appl. Physiol. 2011, 110, 149-156.
20. Cruz-Topete, D., Christensen, B., Sackmann-Sala, L., Okada, S. et al., Serum proteome changes in acromegalic patients following transsphenoidal surgery: novel biomarkers of disease activity. Eur. J. Endocrinol. 2011, 164, 157-167.
21. List, E. O., Berryman, D. E., Palmer, A. J., Gosney, E. et al., Application of bioinformatics and scalable computing to perform proteomic analysis of stomach tissue from diabetic mice. Scalable Comput. Pract. Exp. 2007, 8, 173-183.
22. Daughaday, W. H., Rotwein, P., Insulin-like growth factors I and II. Peptide, messenger ribonucleic acid and gene structures, serum, and tissue concentrations. Endocr. Rev. 1989, 10, 68-91.
23. Yakar, S., Liu, J. L., Fernandez, A. M., Wu, Y. et al., Liver-specific igf-1 gene deletion leads to muscle insulin insensitivity. Diabetes 2001, 50, 1110.
24. Moller, J., Frandsen, E., Fisker, S., Jorgensen, J. O., Christiansen, J. S., Decreased plasma and extracellular volume in growth hormone deficient adults and the acute and prolonged effects of GH administration: a controlled experimental study. Clin. Endocrinol. (Oxf.) 1996, 44, 533-539.
25. Moller, J., Effects of growth hormone on fluid homeostasis. Clinical and experimental aspects. Growth Horm. IGF Res. 2003, 13, 55-74.
26. Ding, J., List, E. O., Okada, S., Kopchick, J. J., Perspective: Proteomic approach to detect biomarkers of human growth hormone. Growth Horm. IGF Res. 2009, 19, 399-407.
27. Weeke, B., Jarnum, S., Serum concentration of 19 serum proteins in Crohn's disease and ulcerative colitis. Gut 1971, 12, 297-302.
28. Schwarzenberg, S. J., Sharp, H. L., Berry, S. A., Manthei, R. D., Seelig, S., Hormonal regulation of serum alpha 1-antitrypsin and hepatic alpha 1-antitrypsin mRNA in rats. Biochem. Biophys. Res. Commun. 1987, 147, 936-941.
29. Schwarzenberg, S. J., Sharp, H. L., Freier, E. F., Seelig, S., Response of serine antiproteases to growth hormone therapy in growth hormone deficient children. Horm. Res. 1989, 31, 221-225.
30. Schydlower, M., Waxman, S. H., Patterson, P. H., Coexistence of deficiency in alpha1 antitrypsin and in growth hormone. N. Engl. J. Med. 1979, 300, 366.
31. Eugster, E. A., Fisch, M., Walvoord, E. C., DiMeglio, L. A., Pescovitz, O. H., Low hemoglobin levels in children with in idiopathic growth hormone deficiency. Endocrine 2002, 18, 135-136.
32. Chung, L., Clifford, D., Buckley, M., Baxter, R. C., Novel biomarkers of human growth hormone action from serum proteomic profiling using protein chip mass spectrometry. J. Clin. Endocrinol. Metab. 2006, 91, 671-677.